Jun 20, 2023Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Mar 30, 2023ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Aug 9, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results